CATALAYER NEWS
Ivonescimab Plus Chemotherapy Demonstrates Overall Survival Superiority Compared to Durvalumab Plus Chemotherapy in First-Line Treatment of Patients with Advanced Biliary Tract Cancer in HARMONi-GI1 Study Conducted by Akeso in China – Compan - Financial Times
Source: Financial Times · 2026-10-25
Full article text is available in the Catalayer news terminal.
MORE FROM FINANCIAL TIMES
Marco Rubio still owes Europe answers about America’s intentions - Financial Times
2026-10-25
Sonesitatug vedotin reduced the risk of death by 42% in 2nd and later-line CLDN18.2-positive advanced gastric/GEJ cancer
2026-10-25
Positive Overall Survival Results from the Phase III HARMONi-GI1 Trial of Ivonescimab Plus Chemotherapy Versus Durvaluma
2026-10-25
TAGRISSO® (osimertinib) plus savolitinib reduced the risk of disease progression or death by 45% and the risk of death b
2026-10-25
Genentech's Divarasib Demonstrated Best-in-Class Efficacy, Advancing the Standard of Care in Previously Treated KRAS G12
2026-10-25
RELATED ON CATALAYER
Related Topics
China Trade & Tech Policy NewsRELATED MARKETS
Prediction Markets